Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1775 plus chemotherapy in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
2015-000886-30Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of adavosertib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started May 2015; status: completed.
02
Drugs
adavosertib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2015-000886-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000886-30.